FLT3 inhibitors for the treatment of autoimmune disease

Author： Whartenby Katharine A   Small Donald   Calabresi Peter A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.11, 2008-11, pp. : 1685-1692

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

By Tickenbrock Lara   Müller-Tidow Carsten   Berdel Wolfgang E   Serve Hubert  

Expert Opinion on Emerging Drugs, Vol. 11, Iss. 1, 2006-03 ,pp. : 153-165

Informa Healthcare

Access to resources Recommend Favorite

Novel FLT3 tyrosine kinase inhibitors

By Levis Mark   Small Donald  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. : 1951-1962

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule FLT3 Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1183-1193

Bentham Science Publishers

Access to resources Recommend Favorite

Interleukin-2 inhibitors in autoimmune disease

By Palanki M.S.   Manning A.M.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 1, 1999-01 ,pp. : 27-39

Informa Healthcare

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite